Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
Provided By GlobeNewswire
Last update: Aug 19, 2024
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders
Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan for Geographic Atrophy
Read more at globenewswire.com
